Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vaia Florou

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal for Immunotherapy of Cancer|November 8, 2019
Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institutionVaia Florou, Andrew E Rosenberg, Eric Wieder, et al.
Investigational New Drugs|December 26, 2024
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancerPatrick M Boland, Heinz-Josef Lenz, Kristen K Ciombor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACCVaia Florou, Andrew Elliott, Matthew H Bailey, et al.
JCO Precision Oncology|August 5, 2024
Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract CancersThejus Jayakrishnan, Yasmine Baca, Joanne Xiu, et al.
JCO Precision Oncology|May 9, 2024
Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic TargetsErik B Faber, Harris B Krause, Khalid Amin, et al.
The Lancet. Oncology|May 13, 2019
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trialBreelyn A Wilky, Matteo M Trucco, Ty K Subhawong, et al.
The Oncologist|December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancerMargaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2020
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2020
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|November 8, 2019
Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institutionVaia Florou, Andrew E Rosenberg, Eric Wieder, et al.
Investigational New Drugs|December 26, 2024
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancerPatrick M Boland, Heinz-Josef Lenz, Kristen K Ciombor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACCVaia Florou, Andrew Elliott, Matthew H Bailey, et al.
JCO Precision Oncology|August 5, 2024
Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract CancersThejus Jayakrishnan, Yasmine Baca, Joanne Xiu, et al.
JCO Precision Oncology|May 9, 2024
Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic TargetsErik B Faber, Harris B Krause, Khalid Amin, et al.
The Lancet. Oncology|May 13, 2019
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trialBreelyn A Wilky, Matteo M Trucco, Ty K Subhawong, et al.
The Oncologist|December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancerMargaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2020
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2020
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, et al.
Pageof 6